 | |
 | |
| Clinical data | |
|---|---|
| Other names | Endiemal, metharbitone, methobarbitone[1] |
| Routes of administration | By mouth (tablets) |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.000.011 |
| Chemical and physical data | |
| Formula | C9H14N2O3 |
| Molar mass | 198.222 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Metharbital was patented in 1905 by Emil Fischer working for Merck.[2] It was marketed as Gemonil by Abbott Laboratories. It is a barbiturate anticonvulsant, used in the treatment of epilepsy.[3][4] It has similar properties to phenobarbital.
History
- 1952 Gemonil was introduced by Abbott Laboratories.
- 1990 Abbott stopped marketing.
Synthesis
Metharbital can be synthesized from 2,2-diethylmalonic acid and O-methylisourea.[5][6][2]
References
- ^ "Metharbital". The Comparative Toxicogenomics Database.
- ^ a b US 782742, Fischer E, "Trisubstituted barbituric acids and process of making them.", issued 14 February 1905, assigned to E. Merck
- ^ Shorvon SR, Fish DR, Perucca E, Dodson WE, eds. (2004). The Treatment of Epilepsy (2nd ed.). Blackwell. ISBN 0-632-06046-8.
- ^ Resor SR (1991). The Medical Treatment of Epilepsy. Marcel Dekker. ISBN 0-8247-8549-5.
- ^ Halpern A, Jones JW (June 1949). "The characterization of the trialkylbarbiturates". Journal of the American Pharmaceutical Association. 38 (6): 352–5. doi:10.1002/jps.3030380619. PMID 18151714.
- ^ Snyder JA, Link KP (1953). "Preparation and Characterization by Alkaline Methanolysis of 5,5-Diethyl-4-(tetraacetyl-β-D-glucosyloxy)-2,6(1,5)-pyrimidinedione". Journal of the American Chemical Society. 75 (8): 1881–1883. doi:10.1021/ja01104a030.
 | This anticonvulsant-related article is a stub. You can help Wikipedia by expanding it. |
This page was last edited on 20 December 2023, at 19:28